



Idenix Pharmaceuticals, Inc.

One Kendall Square
Building 1400
Cambridge MA 02139

Main Tel: 617.995.9800
Main Fax: 617.995.9030
www.idenix.com

January 7, 2007



LETTER OF COMMENT NO. 277

Mr. Robert H. Herz
Chairman, Financial Accounting Standards Board
401 Merritt 7
P.O. Box 5116
Norwalk, CT 06856-5116

Dear Chairman Herz:

On behalf of Idenix Pharmaceuticals, Inc., I strongly urge the Financial Accounting Standards Board to delay the effective date of FIN 48 on Accounting for Uncertainty in Income Taxes to allow companies sufficient time to address the substantive, procedural, and documentation challenges posed by the new interpretation. Specifically, I recommend that the effective date of FIN 48 be deferred to fiscal years beginning after December 15, 2007. The challenges of implementing FIN 48 were articulated by Tax Executives Institute in a letter it sent to you on December 12, 2006.

In summary, extending the deadline for implementing FIN 48 will permit companies and their independent auditors to resolve unanswered questions and thus reduce the likelihood of diversity in practice, which in part prompted the development of FIN 48 in the first instance.

Respectfully,

A handwritten signature in black ink, appearing to read "Peter J. Fipphen".

Peter J. Fipphen
Director, Tax and Treasury